Zobrazeno 1 - 10
of 106
pro vyhledávání: '"A. J. M. Van Den Eertwegh"'
Autor:
J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combin
Externí odkaz:
https://doaj.org/article/ca4c9e5c51fc40759d196932967e286e
Autor:
Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, A. J. M. van den Eertwegh, John B. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christiaan U. Blank, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, A. M. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk, Ellen Kapiteijn
Publikováno v:
Cancers, Vol 16, Iss 15, p 2656 (2024)
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This m
Externí odkaz:
https://doaj.org/article/02c43e3aab1348c3b7328efdfe95b1b5
Autor:
E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two yea
Externí odkaz:
https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9
Autor:
T. D. de Gruijl, G. Giaccone, R. J. Scheper, H. van Cruijsen, K. Hoekman, B. C. Kuenen, A. J. M. van den Eertwegh, A. G. M. Stam
Publikováno v:
Clinical and Developmental Immunology, Vol 2007 (2007)
Externí odkaz:
https://doaj.org/article/ac23ccaa0d9144f6b56c5e3560cd7c41
Autor:
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense‐Den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
International Journal of Cancer, 153, 2, pp. 389-398
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
Contains fulltext : 292870.pdf (Publisher’s version ) (Open Access) Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyon
Autor:
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense‐den Boer, Marye J. Boers‐Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Publikováno v:
van Duin, I A J, Elias, S G, van den Eertwegh, A J M, de Groot, J W B, Blokx, W A M, van Diest, P J, Leiner, T, Verhoeff, J J C, Verheijden, R J, van Not, O J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Haanen, J B A G, Hospers, G A P, Kamphuis, A M, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Stevense-den Boer, M A M, Boers-Sonderen, M J, Kapiteijn, E & Suijkerbuijk, K P M 2023, ' Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma ', International Journal of Cancer, vol. 152, no. 12, pp. 2493-2502 . https://doi.org/10.1002/ijc.34479
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades i
Autor:
Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers
Publikováno v:
Cancers, 15(11):2922. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 15, 11
Cancers, 15
van Not, O J, Wind, T T, Ismail, R K, Bhattacharya, A, Jalving, M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Haanen, J B, Kapiteijn, E, Bloem, M, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Blokx, W A M, Suijkerbuijk, K P M, Fehrmann, R S N & Hospers, G A P 2023, ' A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors ', Cancers, vol. 15, no. 11, 2922 . https://doi.org/10.3390/cancers15112922
Cancers; Volume 15; Issue 11; Pages: 2922
Cancers, 15, 11
Cancers, 15
van Not, O J, Wind, T T, Ismail, R K, Bhattacharya, A, Jalving, M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Haanen, J B, Kapiteijn, E, Bloem, M, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Blokx, W A M, Suijkerbuijk, K P M, Fehrmann, R S N & Hospers, G A P 2023, ' A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors ', Cancers, vol. 15, no. 11, 2922 . https://doi.org/10.3390/cancers15112922
Cancers; Volume 15; Issue 11; Pages: 2922
Contains fulltext : 293454.pdf (Publisher’s version ) (Open Access) The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dcaef79c1a9e25c917f0c8902b4dea0
https://research.vumc.nl/en/publications/3986ca38-c595-4d53-a8ce-8e61d59ddcb4
https://research.vumc.nl/en/publications/3986ca38-c595-4d53-a8ce-8e61d59ddcb4
Autor:
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
Publikováno v:
Annals of Surgical Oncology, 30, 587-588
Annals of surgical oncology, 30(1), 587-588. SPRINGER
Annals of Surgical Oncology, 30, 1, pp. 587-588
Annals of Surgical Oncology, 30, 587-588. SPRINGER
Annals of Surgical Oncology, 30(1), 587-588. Springer New York
Blankenstein, S A, Bonenkamp, J J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Blokx, W A M, Boers-Sonderen, M J, van den Eertwegh, A J M, Franken, M G, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, van der Veldt, A A M, Vreugdenhil, G, Westgeest, H M, Wouters, M W J M & van Akkooi, A C J 2023, ' ASO Visual Abstract : Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? ', Annals of Surgical Oncology, vol. 30, no. 1, pp. 587-588 . https://doi.org/10.1245/s10434-022-12719-2
Annals of surgical oncology, 30(1), 587-588. SPRINGER
Annals of Surgical Oncology, 30, 1, pp. 587-588
Annals of Surgical Oncology, 30, 587-588. SPRINGER
Annals of Surgical Oncology, 30(1), 587-588. Springer New York
Blankenstein, S A, Bonenkamp, J J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Blokx, W A M, Boers-Sonderen, M J, van den Eertwegh, A J M, Franken, M G, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, van der Veldt, A A M, Vreugdenhil, G, Westgeest, H M, Wouters, M W J M & van Akkooi, A C J 2023, ' ASO Visual Abstract : Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? ', Annals of Surgical Oncology, vol. 30, no. 1, pp. 587-588 . https://doi.org/10.1245/s10434-022-12719-2
Item does not contain fulltext 01 januari 2023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1480b0963fbc242733d1a1605fef0bb9
http://hdl.handle.net/2066/290963
http://hdl.handle.net/2066/290963
Autor:
Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. Van Not, Djura Piersma, Rozemarijn S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. Van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. Van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
Cancers, 15(2):409. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 15(2). MDPI
Cancers, 15, 2
de Meza, M M, Blokx, W A M, Bonenkamp, J J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma : A Propensity-Matched Outcome Analysis ', Cancers, vol. 15, no. 2, 409 . https://doi.org/10.3390/cancers15020409
Cancers; Volume 15; Issue 2; Pages: 409
Cancers, 15
Cancers, 15(2). MDPI
Cancers, 15, 2
de Meza, M M, Blokx, W A M, Bonenkamp, J J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma : A Propensity-Matched Outcome Analysis ', Cancers, vol. 15, no. 2, 409 . https://doi.org/10.3390/cancers15020409
Cancers; Volume 15; Issue 2; Pages: 409
Cancers, 15
Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of stage III melanoma in patients with BRAF V600 mutations in clinical trials. However, little is known about how these therapies compare to each other i
Autor:
Christian U. Blank, John B. A. G. Haanen, Doranne L. Hilarius, Michel W. J. M. Wouters, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Rawa K. Ismail, Geke A. P. Hospers, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Maureen J.B. Aarts, D Piersma, Astrid A M van der Veldt, G. Vreugdenhil, Marion A. M. Stevense-den Boer, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Olivier J. van Not, Melissa M. De Meza
Publikováno v:
International Journal of Cancer, 150(5), 816-824. Wiley
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer
The COVID‐19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID‐19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma during the f